|
Malignant neoplasm of breast
|
0.380 |
Biomarker
|
disease |
BEFREE |
EMSY is located in the breast cancer-associated chromosomal region 11q13.
|
28738860 |
2017 |
|
Malignant neoplasm of breast
|
0.380 |
Biomarker
|
disease |
BEFREE |
Altogether, these results suggest a pathway underlying the role of EMSY in breast cancer and uncover potential diagnostic and therapeutic targets in sporadic breast cancer.
|
24582497 |
2014 |
|
Malignant neoplasm of breast
|
0.380 |
Biomarker
|
disease |
BEFREE |
Compared to female breast cancers, EGFR (p = 0.005) and CCND1 (p = 0.041) copy number gain was more often seen in male breast cancer, while copy number gain of EMSY (p = 0.004) and CPD (p = 0.001) and amplification in general was less frequent.
|
22527098 |
2012 |
|
Malignant neoplasm of breast
|
0.380 |
Biomarker
|
disease |
BEFREE |
As EMSY is located on 11q13 in proximity to CCND1, an established breast cancer oncogene, we also examined the amplification of CCND1 in the same tumor cohort.
|
21327470 |
2011 |
|
Malignant neoplasm of breast
|
0.380 |
Biomarker
|
disease |
CTD_human |
Here, we investigate the prognostic significance of CCND1 and EMSY amplification in a large series of breast carcinomas and in BRCA1 and BRCA2 mutation positive breast cancers.
|
19636701 |
2010 |
|
Malignant neoplasm of breast
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
Here, we investigate the prognostic significance of CCND1 and EMSY amplification in a large series of breast carcinomas and in BRCA1 and BRCA2 mutation positive breast cancers.
|
19636701 |
2010 |
|
Malignant neoplasm of breast
|
0.380 |
Biomarker
|
disease |
BEFREE |
Genetic alterations of CCND1 and EMSY in breast cancers.
|
18393977 |
2008 |
|
Malignant neoplasm of breast
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
These results support the hypothesis that EMSY overexpression can play a role in the genesis of human breast cancer.
|
16145051 |
2005 |
|
Malignant neoplasm of breast
|
0.380 |
Biomarker
|
disease |
BEFREE |
EMSY links breast cancer gene 2 to the 'Royal Family'.
|
15318925 |
2004 |
|
Breast Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
EMSY is located in the breast cancer-associated chromosomal region 11q13.
|
28738860 |
2017 |
|
Breast Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
Altogether, these results suggest a pathway underlying the role of EMSY in breast cancer and uncover potential diagnostic and therapeutic targets in sporadic breast cancer.
|
24582497 |
2014 |
|
Breast Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
As EMSY is located on 11q13 in proximity to CCND1, an established breast cancer oncogene, we also examined the amplification of CCND1 in the same tumor cohort.
|
21327470 |
2011 |
|
Breast Carcinoma
|
0.370 |
Biomarker
|
disease |
CTD_human |
Here, we investigate the prognostic significance of CCND1 and EMSY amplification in a large series of breast carcinomas and in BRCA1 and BRCA2 mutation positive breast cancers.
|
19636701 |
2010 |
|
Breast Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
Here, we investigate the prognostic significance of CCND1 and EMSY amplification in a large series of breast carcinomas and in BRCA1 and BRCA2 mutation positive breast cancers.
|
19636701 |
2010 |
|
Breast Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
CCND1 and EMSY, on 11q13, are frequently amplified in breast cancer.
|
18393977 |
2008 |
|
Breast Carcinoma
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
These results support the hypothesis that EMSY overexpression can play a role in the genesis of human breast cancer.
|
16145051 |
2005 |
|
Breast Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
EMSY links breast cancer gene 2 to the 'Royal Family'.
|
15318925 |
2004 |
|
Dermatitis, Atopic
|
0.330 |
Biomarker
|
disease |
BEFREE |
Skin biopsy samples from patients with AD show greater EMSY staining in the nucleus, which is consistent with an increased functional effect of this transcriptional control protein.
|
31158401 |
2019 |
|
Dermatitis, Atopic
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
Interestingly, the IL1RL1, HLA, IL13 and C11orf30 regions are overlapping susceptibility loci among atopic dermatitis and asthma or allergic rhinitis.
|
23439055 |
2013 |
|
Dermatitis, Atopic
|
0.330 |
Biomarker
|
disease |
CTD_human |
We also replicated the associations of the FLG, C11orf30, TMEM232-SLC25A46, TNFRSF6B-ZGPAT, OVOL1, ACTL9 and KIF3A-IL13 loci that were previously reported in GWAS of European and Chinese individuals and a meta-analysis of GWAS for atopic dermatitis.
|
23042114 |
2012 |
|
Dermatitis, Atopic
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
Variants in a locus near chromosome 11 open reading frame 30 (C11orf30) and leucine-rich repeat containing 32 (LRRC32), which was previously associated with atopic dermatitis and eczema, were also strongly associated with both phenotypes (rs2155219; P(grass) = 9.4 × 10(-9); P(AR) = 3.8 × 10(-8)).
|
22036096 |
2011 |
|
Mammary Neoplasms
|
0.320 |
GeneticVariation
|
group |
BEFREE |
We hypothesized that breast tumors from BRCA2 mutation carriers would be less likely than other familial breast cancers to exhibit EMSY amplification.
|
21327470 |
2011 |
|
Mammary Neoplasms
|
0.320 |
Biomarker
|
group |
CTD_human |
Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers.
|
19636701 |
2010 |
|
Mammary Neoplasms
|
0.320 |
AlteredExpression
|
group |
LHGDN |
Genomic instability of human mammary epithelial cells overexpressing a truncated form of EMSY.
|
16145051 |
2005 |
|
Prostate cancer, familial
|
0.300 |
Biomarker
|
disease |
CTD_human |
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.
|
29892016 |
2018 |